 Randomized controlled trials  Adults ≥ 18 years old with hypertension  N >100  Duration: ≥ 1 year  Outcomes  Mortality, CVD related-mortality,

Slides:



Advertisements
Similar presentations
Resistant and Secondary Hypertension
Advertisements

Review of the 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults – JNC 8 Eighth National Joint Committee Amanda Birnschein,
Making Sense of the New Guidelines: Hypertension The More We Learn, the Less We Know Zeb K. Henson, M.D. Assistant Professor, Department of Medicine &
11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.
MU Family Medicine Algorithms Algorithms/Pathways are based on national guidelines with modification for local practice. They do not replace clinical judgment,
Hypertension Management: Thinking Outside the Protocol Seuli Bose Brill, MD ACC Ambulatory Conference January 7, 2009 Review of the ACCOMPLISH trial and.
Etiology Primary hypertension 95% of all cases Secondary hypertension – 5% of all cases – Chronic renal disease – most common White coat hypertension –
Review cases 14-Apr SA is a 47 years old male who developed crushing substernal chest pain around 10 pm, he didn’t went to the hospital, in the.
Hypertension Guidelines 2014
Updates on the Management of Hypertension A Review of the JNC8 Guidelines Timothy Gladwell, Pharm.D., BCPS, BCACP Associate Professor and Vice Chair Department.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
Refractory Hypertension: Four Cases Paul R. Chelminski, MD, MPH, FACP Associate Professor of Medicine Associate Residency Program Director.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Blood Pressure Control and Treatment in the CKD Patient Horacio E. Adrogue, MD James M. Atkins, MD Chester H. Fox, MD, FAAFP Jacqueline Nolen, PharmD.
Hypertension: what is new…and old GREG FOTIEO, MD.
Chronic Kidney Disease: A Silent Epidemic (Case Review) Naima Ogletree, MSN, APRN, BC Nephrology & Hypertension Henry Ford Health System.
Clinical Update on the JNC 7/8 Hypertension Guidelines
Hypertension and The Older Patient
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Selection of Antihypertensive Drug
Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.
Management of Hypertension Laura Fitzpatrick, MD, MPH Intern Academics Friday the 13 th, August 2004.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Blood Pressure Control in Hispanics in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Karen L. Margolis, Linda.
 A 59F diagnosed with HTN 8 years ago comes to the clinic for BP check. She is currently taking HCTZ 25 mg/d, lisinopril 40 mg/d and amlodipine 10 mg/d.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
 Update on Hypertension Troy L. Randle, DO, FACC, FACOI.
Hypertension Guidelines 2015 Barry D. Bertolet, MD Cardiology Associates of North Mississippi Tupelo – Columbus – Starkville - Oxford.
CHRISTIAN SONNIER MD 7/15/14 Hyperlipidemia:. Hyperlipidemia Definition: an elevation of total cholesterol and or LDL with or without decrease in HDL.
Case Studies Group Activity Each group will receive the first slides of a case study Each group will have about 15 min to review and answer questions Each.
2013 American College of Cardiology American Heart Association.
Patient case studies. JR is a 72 YO male with CHF, LVEF=32%. T2DM, HTN His meds include carvedilol 12.5mg q12hr, furosemide 40mg q day, and kcl 20meq.
Hypertension  Classification of hypertension  BP targets  Basic evaluation  When to evaluate for secondary causes  Which drug(s) you should use 
Cardiovascular Update
Common Medications used in the ESRD Population Mary Kay Carone NP.
1 Review of the Design and Initial Findings for Pre-specified Outcomes and Subgroups Paul K. Whelton, M.D., M.Sc. Loyola University Medical Center Maywood,
Hypertension Mohammad Garakyaraghi,MD Cardiologist Associate Professor.
Drug List Accupril Quinapril – ACE Inhibitor – HTN & CHF.
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
Health Promotion and Wellness GNRS 5521: Clinical Role Practicum Case Presentation by Elizabeth Lopez On January 27, 2014 ____________________________________________.
Journal Club Jeffrey P Schaefer, MD April 16, 2007.
PHARMACOTHERAPY OF HYPERTENSION Based on New Guidelines Fariborz Nikaeen; MD Interventional cardiologist 2 november 2015.
Hypertension: Case Studies Michael Soung, MD, FACP Virginia Mason Medical Center General Internal Medicine.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Cardiovascular Outcomes in Hypertensives with CHD Randomized to Amlodipine versus Lisinopril in ALLHAT Frans Leenen MD, PhD, Chuke Nwachuku MA, MPH, Dr.
April 22, 2016 Connie Tien Daniel Kim Jeffrey Hughes Michelle Di Fiore
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Managing Blood Pressure in the Older Adult Jamie McCarrell, Pharm.D., BCPS, CGP TTUHSC School of Pharmacy.
+ Therapeutics 1 Tutoring Sarah Darby August 18, 2016.
+ Therapeutics 1 Tutoring Sarah Darby October 3, 2016.
Therapeutics Tutoring
Hypertension Guidelines-JNC 8
Health and Human Services National Heart, Lung, and Blood Institute
T1: Post ACS Treatment Tutoring
Dyslipidemia and Primary Prevention
Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.
Jeannine Costigan RN(EC) Nurse Practitioner Heart Function Clinic
Jeannine Costigan RN(EC) Nurse Practitioner Heart Function Clinic
Health and Human Services National Heart, Lung, and Blood Institute
Background for understanding the Hypertension literature.
RCHC’s Cardiovascular Health Initiative
Jeannine Costigan RN(EC) Nurse Practitioner Heart Function Clinic
(Dueling) Hypertension Guidelines: Focus on ACC/AHA Guidelines
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Heart Failure through the Ages
Post-Heart Failure Mortality
Approach to hypertension
Presentation transcript:

 Randomized controlled trials  Adults ≥ 18 years old with hypertension  N >100  Duration: ≥ 1 year  Outcomes  Mortality, CVD related-mortality, CKD-related mortality  MI, HF, hospitalization-HF  Coronary or other revascularization  ESRD ▪ KF resulting in dialysis or transplantation, doubling of Cr value, halving of GFR

 In adults with HTN,  Does initiating antihypertensive drug therapy at specific BP thresholds improve health outcomes?  Does treatment with antihypertensive drug therapy to a specified goal lead to improvement in health outcomes?  Do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcomes?

45 y.o. white female Hx: HTN, hyperlipidemia, MDD Meds: Atorvastatin 20mg QD, Fluoxetine 20mg QD BP: 150/96, HR: 73 Treatment: 1. Lisinopril 10mg QD 2. Amlodipine 5mg 3. HCTZ mg QD 4. Metoprolol BID 10

64 y.o. white male Hx: CKD, HTN, hyperlipidemia Meds: simvastatin 20mg QD, ASA 81mg QD, lisinopril 20mg QD Labs: Cr = 1.9, K+ = 4.8, Est Clcr = 38 ml/min BP: 152/94, HR: 68 Treatment: 1. HCTZ mg QD 2. Amlodipine 5mg QD 3. Losartan 50mg QD 4. Increase lisinopril to 40mg QD 10

56 y.o. black male Hx: diabetes, HTN, obstructive sleep apnea Meds: metformin 1000mg BID, ASA 81mg QD, Gluctotrol XL 10mg QD Labs: Cr = 1.0 BP: 148/88, HR: 70 Treatment: 1. lisinopril 10mg QD 2. losartan 50mg QD 3. HCTZ mg QD 4. Furosemide 20mg QD 10

67 y.o. white male Hx: HTN, DM, hyperlipidemia, GERD, BPH Meds: finasteride 5mg QD, Zocor 80mg QD, terazosin 10mg QD, glimepride 4mg QD, Actos 45mg QD, lisinopril 10mg QD, metformin XR 2000mg/d, ASA 81mg QD Labs: Cr: 1.2, microalbumin 10mg/L, K+ = 4.3 BP: 160/88,HR: 57 Treatment 1. HCTZ mg QD 2. Hydralazine 25mg BID 3. Diltiazem XR 180mg QD 4. Increase lisinopril to 20mg QD 10

77 y.o. female Hx: HTN, osteoporosis, angina, GERD Meds: Reclast 5mg Qyear, Prilosec 40mg QD, Toprol XL 100mg QD, ASA, lisinopril/HCTZ 20/25mg QD BP: 169/66, HR: 57, weight: 100 lbs, Cr = 0.3, K+ = 4.2 Treatment: 1. Terazosin 2. Amlodipine 3. Hydralazine 4. Furosemide 10

78 y.o. female Hx: Afib (c/o palpitations), HTN Meds: warfarin, metoprolol 100mg BID, losartan 50mg QD BP: 154/82 HR: 90 Treatment 1. Amlodipine 2. Diltiazem XR 3. Spironolactone 4. Furosemide 10

66 y.o. black male Hx: HTN, s/p MI 2 months ago, hyperlipidemia Meds: atorvastatin 20mg QD, ASA 81mg QD, Plavix 75mg QD, HCTZ 25mg QD, metoprolol 100mg BID BP: 152/92, HR: 62 Treatment 1. Amlodipine 2. Lisinopril 3. Diltiazem XR 4. Furosemide 10

66 y.o. male Hx: CKD, HTN, diabetes, PAD, hypothyroidism, hyperlipidemia Meds: ASA 81mg QD, Lantus + Humalog, levothyroxine 0.1mg QD, Crestor 20mg QD, lisinopril 20mg QD Labs: Cr = 2.8, K+ = 4.8 BP: 150/92, HR: 68 Treatment 1. atenolol 2. amlodipine 3. HCTZ 4. hydralazine 10

70 y.o. male Hx: HTN, LVH, GERD, TIA Meds: Plavix 75mg QD, famotidine 20mg QD, HCTZ 25mg QD BP: 154/86, HR: 70 Treatment 1. Metoprolol 2. Lisinopril 3. Amlodipine 4. Spironolactone 10

62 y.o. female Hx: COPD, HTN, OA, obesity, CAD, occ symptomatic angina Meds: Spiriva, Advair, ASA, Imdur 90mg QD, lisinopril 40mg QD, metoprolol XL 100mg QD, Nitrostat PRN BP: 152/90, HR: 64 Treatment 1. HCTZ 2. valsartan 3. amlodipine 4. terazosin 10

 Age ≥ 60: goal BP is <150/90  Age <60: goal BP is <140/90  First line therapies  Thiazide, CCB’s, ACEI, ARB  Thiazide or CCB recommended over ACEI in blacks with diabetes  Beta-blockers: not recommended as first line therapy